Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results

doi:10.3969/j.issn.1673-8640.2023.04.010

Abstract

Abstract:

Objective To compare severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） neutralizing antibody and specific antibody determination results，and to provide a reference for clinical interpretation of specific antibody determination results in vaccinated population. Methods Totally，148 health care personnels who were excluded from SARS-CoV-2 infection were enrolled. Among them，127 cases were inoculated with SARS-CoV-2 vaccine，and they were classified into 14-30 d group，31-60 d group，61-90 d group，91-120 d group，121-150 d group and >150 d group according to the time interval between the date of sample collection and the date of the second injection of vaccine. Totally，21 cases were not inoculated with SARS-CoV-2 vaccine. Lateral flow immunoassay（LFIA） and enzyme-linked immunosorbent assay（ELISA） were used to determine SARS-CoV-2 neutralizing antibodies，and magnetic particle chemiluminescence immunoassay was used to determine SARS-Cov-2 specific IgM and IgG antibodies. The consistency of 3 methods was analyzed. Results The positive rates of ELISA neutralizing antibody，LFIA neutralizing antibody and specific IgG antibody were 100.00%，and the positive rate of specific IgM antibody was 27.27% in the 14-30 d group. With the extension of vaccination time，the positive rates of the 3 methods were decreased gradually. The positive rate of specific IgG antibody was the highest in 31-120 d groups，and the positive rate of ELISA neutralizing antibody was the highest in 121-150 d group and >150 d group. The total consistency between ELISA and LFIA for neutralizing antibody was 85.14%，and the Kappa value was 0.698. The total consistency for specific IgM antibody was 60.14%，and the Kappa value was 0.144. The total consistency for specific IgG antibody was 82.43%，and the Kappa value was 0.649. The total consistency of specific IgG antibody and LFIA neutralizing antibody was 83.78%，and the Kappa value was 0.677. Conclusions The consistency between the determination results of specific IgG antibody by magnetic particle chemiluminescence immunoassay and the determination results of neutralizing antibody by LFIA and ELISA is >80%，and the consistency is general. The positive results of specific IgG antibody should be interpreted with caution.

Key words: Severe acute respiratory syndrome coronavirus 2, Specific antibody, Neutralizing antibody, Enzyme-linked immunosorbent assay, Colloidal gold immunochromatography, Magnetic particle chemiluminescence immunoassay

CLC Number:

R373.1

XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results[J]. Laboratory Medicine, 2023, 38(4): 352-356.

Figures/Tables 3

References 13.

1.	曹雪涛. 新型冠状病毒肺炎及新发传染病之免疫学研究[J]. 中华医学杂志, 2021, 101(1):1-6.
2.	JU B, ZHANG Q, GE J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature, 2020, 584(7819):115-119. DOI
3.	吴雯, 周贵香, 施超, 等. 新型冠状病毒感染者特异性抗体变化特征分析[J]. 中国公共卫生, 2022, 38(6):804-807.
4.	GEURTSVANKESSEL C H, OKBA N M A, IGLOI Z, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment[J]. Nat Commun, 2020, 11(1):3436. DOI PMID
5.	KRAUSE P R, FLEMING T R, LONGINI I M, et al. SARS-CoV-2 variants and vaccines[J]. N Engl J Med, 2021, 385(2):179-186. DOI URL
6.	CAINI S, BELLERBA F, CORSO F, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications[J]. Euro Surveill, 2020, 25(23):2000980.
7.	陈维欣, 陈萌, 周珊珊, 等. 新型冠状病毒疫苗免疫后抗体水平检测的3种实验方法比较[J]. 中华微生物学和免疫学杂志, 2021, 41(6):423-426.
8.	ZHANG Y, ZENG G, PAN H, et al. Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21(2):181-192. DOI URL
9.	田亚玲, 鲁君艳. SARS-CoV-2 N蛋白和S蛋白抗体检测在COVID-19诊断中的应用[J]. 检验医学, 2020, 35(11):1136-1139.
10.	赵宏婷, 彭质斌, 杨孝坤, 等. 新型冠状病毒感染者特异性抗体动态变化特征研究进展[J]. 中华流行病学杂志, 2021, 42(1):39-43.
11.	王丹, 于海立, 张露方, 等. 国产新型冠状病毒抗体胶体金法检测试剂盒在低流行区应用的诊断效果评价[J]. 现代检验医学杂志, 2021, 36(3):103-107.
12.	金晶, 边春红, 聂秀娟, 等. 化学发光法检测新型冠状病毒特异性抗体的假阳性结果评价[J]. 标记免疫分析与临床, 2021, 28(6):1045-1050.
13.	李小凤, 姜海蓉, 王静, 等. 免疫荧光层析法检测新型冠状病毒IgM/IgG抗体的临床价值及假阳性分析[J]. 标记免疫分析与临床, 2021, 28(2):246-250.

组别	例数	LFIA中和抗体/ [例（%）]	ELISA中和抗体/[例（%）]	特异性IgG抗体/ [例（%）]	特异性IgM抗体/ [例（%）]
14~30 d组	11	11（100.00）	11（100.00）	11（100.00）	3（27.27）
31~60 d组	31	21（67.74）	19（61.29）	27（87.10）	4（12.90）
61~90 d组	12	6（50.00）	7（58.33）	10（83.33）	2（16.67）
91~120 d组	12	5（41.67）	5（41.67）	8（66.67）	0（0）
121~150 d组	50	15（30.00）	22（44.00）	18（36.00）	2（4.00）
>150 d组	11	1（9.09）	2（18.18）	1（9.09）	0（0）
合计	127	59（46.46）	66（51.97）	75（59.06）	11（8.66）

组别	例数	LFIA中和抗体/ [例（%）]	ELISA中和抗体/[例（%）]	特异性IgG抗体/ [例（%）]	特异性IgM抗体/ [例（%）]
14~30 d组	11	11（100.00）	11（100.00）	11（100.00）	3（27.27）
31~60 d组	31	21（67.74）	19（61.29）	27（87.10）	4（12.90）
61~90 d组	12	6（50.00）	7（58.33）	10（83.33）	2（16.67）
91~120 d组	12	5（41.67）	5（41.67）	8（66.67）	0（0）
121~150 d组	50	15（30.00）	22（44.00）	18（36.00）	2（4.00）
>150 d组	11	1（9.09）	2（18.18）	1（9.09）	0（0）
合计	127	59（46.46）	66（51.97）	75（59.06）	11（8.66）

特异性IgG抗体	ELISA中和抗体^*		LFIA中和抗体^**
特异性IgG抗体	阳性	阴性	阳性	阴性
阳性	59	17	56	20
阴性	9	63	4	68
合计	68	80	60	88

特异性IgG抗体	ELISA中和抗体^*		LFIA中和抗体^**
特异性IgG抗体	阳性	阴性	阳性	阴性
阳性	59	17	56	20
阴性	9	63	4	68
合计	68	80	60	88

[1]	SUN Xinlin, YE Xingming, LI Qian, ZHAO Lijun. Bronchoscopy combined with sputum Mycobacterium tuberculosis ribonucleic acid and serum Mycobacterium tuberculosis specific antibody determinations for diagnosis of negative pulmonary tuberculosis [J]. Laboratory Medicine, 2023, 38(9): 870-873.
[2]	YANG Xue, ZHU Jun, JIANG Lingli, WANG Qing, HU Xiaobo. Evaluation on the consistency of blind sample test results of 9 SARS-CoV-2 nucleic acid determination kits in Shanghai，China [J]. Laboratory Medicine, 2023, 38(8): 776-780.
[3]	ZENG Yanfen, WU Quanming, ZHOU Huan, ZHANG Qiuqin, KANG Yanli, LI Yao, CHEN Xijun, HUANG Jiangang, CHEN Falin. Determination limits of a severe acute respiratory syndrome coronavirus 2 nucleic acid determination reagent in 4 determination systems [J]. Laboratory Medicine, 2023, 38(3): 261-266.
[4]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[5]	YANG Danping, WANG Hong, WANG Can, CHEN Wei, YANG Aiping. Diagnostic efficacy and clinical application evaluation of SARS-CoV-2 antigen determination [J]. Laboratory Medicine, 2023, 38(1): 28-31.
[6]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.
[7]	TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function [J]. Laboratory Medicine, 2022, 37(8): 729-734.
[8]	CHEN Qian, SHAN Zhiming, SONG Chao, KANG Fengfeng, JIN Jing, LI Weixing. Status of quality management of new laboratories for nucleic acid determination of SARS-CoV-2 in Zhejiang [J]. Laboratory Medicine, 2022, 37(7): 669-673.
[9]	SUN Ying, LI Yi, YAN Wenjuan, JING Nan, MA Bing. Analysis of drug resistance of rare CRE and clinical application of carbapenem screening test in Henan [J]. Laboratory Medicine, 2022, 37(2): 146-149.
[10]	GE Yanmei, HAN Jianxiang, JI Wenli, GAO Daqing, TONG Huacheng. Analysis of serum SARS-CoV-2 IgM,IgG and neutralizing antibody levels in an adult population vaccinated with SARS-CoV-2 [J]. Laboratory Medicine, 2022, 37(1): 47-50.
[11]	YAO Lifeng, ZHENG Qiaoping, YANG Meng, LUO Qingqiong, CHEN Xu, CHEN Fuxiang. Evaluation of colloidal gold immunochromatography assay for the rapid determination of carbapenemase in CRE isolates [J]. Laboratory Medicine, 2022, 37(1): 68-71.
[12]	ZHANG Yunli, WANG Xin, SHAO Ling, QU Bo, ZHAO Hongmei. Comparison of different nucleic acid extraction methods for the detection of SARS-Cov-2 [J]. Laboratory Medicine, 2021, 36(5): 530-534.
[13]	HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559.
[14]	CHEN Jianbo, YANG Yong, LI Huiyuan, REN Chanjun, DU Juan, LI Genshi, TAO Ran, CHEN Jingxian, ZHANG Ling, LI Miao. Comparison of 4 commercial kits for detecting SARS-CoV-2 nucleic acid [J]. Laboratory Medicine, 2021, 36(4): 396-399.
[15]	HUANG Fei, ZHANG Chunyan, PAN Baishen, WANG Beili, GUO Wei. Advance in the technologies of molecular assays for SARS-CoV-2 [J]. Laboratory Medicine, 2021, 36(4): 462-466.